TSMC (TSM.US) is amid capacity bottlenecks, while a few years ago, he would have described TSMC's capacity as unlimited, said Natarajan Ramachandran, Product Sales Director for the Physical Layer Products Division at Broadcom (AVGO.US), Reuters reported.

He noted that TSMC plans to increase capacity by next year, but its capacity has already met a bottleneck, or in some sense, a blockage in the supply chain this year.

He warned that the shortage phenomenon is not limited to semiconductors but has also spread to multiple related supply chains.

Despite the presence of many suppliers in the industry today, there are indeed supply constraints in the laser field, and printed circuit boards (PCBs) have unexpectedly hit a bottleneck.
~


AASTOCKS Financial News
Website: www.aastocks.com

HONG KONG, March 25, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK)  ("Akeso" or the "Company") announced today that it has received clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to initiate Phase II clinical trials for AK146D1, a first-in-class Trop2 /Nectin4 bispecific antibody-drug conjugate (ADC), and AK138D1, an innovative HER3-targeting ADC.

The studies will evaluate these two novel ADC candidates in combination with the Company's pioneering immuno-oncology (IO) 2.0 bispecific antibodies, cadonilimab (PD-1/CTLA-4) and ivonescimab (PD-1/VEGF), as well as other proprietary high-potential anti-tumor assets, including AK117 (anti-CD47 monoclonal antibody) and AK109 (anti-VEGF monoclonal antibody), across a spectrum of advanced solid tumors. This milestone marks a strategic acceleration of Akeso's proprietary "IO 2.0 + ADC 2.0" combination platform into mid-stage clinical development.

These Phase II studies will leverage the cadonilimab and ivonescimab as foundational backbone therapies, capitalizing on their validated clinical profiles in checkpoint blockades and dual VEGF/PD-1 inhibition. The regimens center on Akeso's internally discovered next-generation ADCs while exploring synergies with the company's broader internal portfolio.

The convergence of immuno-oncology and ADC modalities has emerged as a high-conviction frontier in oncology therapy, offering the potential to overcome the limitations of monotherapy approaches – such as antigen escape, heterogeneous expression, and narrow therapeutic indices. Akeso holds a distinct global competitive advantage as the only company with two approved cancer immunotherapy checkpoint bispecific antibodies. By pairing these IO backbones with next-generation ADC candidates like AK146D1 and AK138D1, the Company is driving the next generation of combination therapy. AK146D1 and AK138D1 have been specifically designed to expand the therapeutic window and mitigate safety-related limitations of traditional ADCs. The progression of these "IO 2.0 + ADC 2.0" combinations into Phase II development is a significant step in establishing Akeso's next-generation leadership in the global oncology landscape.

AK146D1 is a first-in-class bispecific ADC engineered to simultaneously target Trop2 and Nectin4, antigens that are frequently co-expressed in epithelial-derived malignancies such as lung, breast, and bladder cancers. This dual-targeting approach is designed to enhance selectivity, address tumor heterogeneity, and overcome the resistance mechanisms common in single-target ADC therapies. AK138D1 is a next-generation ADC targeting HER3, a receptor associated with tumor progression and resistance to established EGFR and HER2 treatments in various malignancies, including ovarian, colorectal, melanoma, and prostate cancers. Early-stage data for both AK146D1 and AK138D1 have demonstrated potent anti-tumor activity and a highly manageable safety profile.

Akeso continues to extend its global IO 2.0 leadership into broader, high-impact combination strategies. Beyond the "IO 2.0 + ADC 2.0" portfolio, the Company is advancing a comprehensive portfolio of novel combination approaches aimed at addressing major unmet clinical needs. These include IO 2.0 combinations with other immune checkpoint inhibitors (ICIs), mRNA-based personalized cancer vaccines (such as AK154), DNA-based therapeutics, and additional novel therapeutic platforms. 

This milestone underscores Akeso's disciplined execution in translating proprietary platform synergies into clinical progress, positioning the Company at the forefront of next-generation global oncology innovation.

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its proprietary Tetrabody multi-specific antibody platform, Dual-Shield Antibody-Drug Conjugates (ADCs), Dual-Lock T-cell engager (TCE), Tissue-Smart siRNA, Cell Therapies, and Flex-Nano mRNA platforms. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization model, the company has evolved into a globally competitive biopharmaceutical focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 27 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

Forward-Looking Statements

This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

In February 2026, China saw the installation volume of new energy vehicle (NEV) power batteries drop by 19.2% YoY to 27.3 GWh, according to an insight report released by the China Passenger Car Association (CPCA).

In 2M26, the average battery capacity per NEV was 62 kWh, up 29.2% YoY. XIAOMI-W (01810.HK), BYD COMPANY (01211.HK), and Tesla (TSLA.US) were the main contributors to the power battery installation volume.
~



AAStocks Financial News
Web Site: www.aastocks.com

SpaceX plans to submit its IPO prospectus to US regulators later this week or next week, The Information reported, citing sources.

It is understood that this IPO aims to raise over USD75 billion, and SpaceX may go public in June, with individual investor allocation possibly exceeding 20%, though the exact proportion has yet to be finalized.
~



AAStocks Financial News
Web Site: www.aastocks.com

Crude oil prices re-escalated as the Iran war entered its fourth week, leading to a retreat in US bourse Tuesday. The Nasdaq charted the wildest downswing, ending down 184 points or 0.8% at 21,761. The S&P 500 closed down 24 points or 0.4% at 6,556. The DJIA settled down 84 points or 0.2% at 46,124.

Software stocks came under pressure, with Salesforce (CRM.US) sliding more than 6%. Most tech stocks slumped, as Microsoft (MSFT.US) rented Texas data center dropped by OpenAI and Oracle (ORCL.US), causing Microsoft to sag over 2%. Amazon (AMZN.US) saw its Bahrain services disrupted again by the Iran conflict, falling 1.4%.
~



AASTOCKS Financial News
Website: www.aastocks.com

Arm (ARM.US) announced on Tuesday the launch of its new AI data center chip, the AGI CPU, which is planned to enter mass production in the second half of this year and is expected to generate billions of USD in revenue.

The AGI CPU is designed to handle data computations required for a certain type of artificial intelligence that can act on behalf of users with minimal supervision, rather than responding to queries like chatbots.

Meta (META.US) will be the primary partner for Arm's AGI CPU. Arm's new chip clients include OpenAI, Cloudflare (NET.US), SAP, and SK Telecom.
~



AASTOCKS Financial News
Website: www.aastocks.com

• 營收約20.5792億元，毛利約14.7878億元，實現同比增長。
• 研發開支約13.1968億元。
• 期內虧損3.8197億元，調整後年度虧損^[1]約2.1128億元。
• 現金及金融資產^[2]約45.5936億元，現金儲備充足。
• 資產負債率^[3]進一步降至18.7%。

成都2026年3月25日 /美通社/ -- 四川科倫博泰生物醫藥股份有限公司（以下簡稱「科倫博泰」或「該公司」，股票代碼：6990.HK）公佈其截至2025年12月31日（以下簡稱「報告期」）的年度經審核合併業績。

科倫博泰正憑借其核心優勢和專有的OptiDC™技術平台，持續深耕抗體偶聯藥物(ADC)及新型偶聯藥物(DC)領域。公司積極推進包括雙特異性ADC、放射性核素偶聯藥物(RDC)、免疫刺激ADC (iADC)及降解抗體偶聯藥物(DAC)等前沿藥物形式，著力構建具有強大全球競爭力的差異化研發管線。同時，科倫博泰穩步推進產品商業化進程，實現業務轉型增長。截至目前，公司已有四款產品（共覆蓋8個適應症）在中國獲批上市，包括注射用蘆康沙妥珠單抗（佳泰萊R）、注射用博度曲妥珠單抗（舒泰萊R）、塔戈利單抗注射液（科泰萊R）和西妥昔單抗N01注射液（達泰萊R）。其中，三款產品（共覆蓋5個適應症）已被納入2025年國家醫保藥品目錄，構建起覆蓋研發至商業化的全鏈條藥物開發生態系統。

截至目前，公司已構建起包含30餘款在研藥物的強大研發管線，其中10餘款處於臨床階段，並逐步拓展至自身免疫性疾病、代謝性疾病等更廣泛的非腫瘤治療領域。展望未來，公司將依托其創新且差異化的研發管線，為全球尚未滿足的重大醫療需求提供高質量的治療方案。

核心ADC產品商業化落地，夯實長期業績基礎

注射用蘆康沙妥珠單抗（sac-TMT，TROP2 ADC）（亦稱SKB264/MK-2870）（商品名：佳泰萊^R）

三陰性乳腺癌：

• 公司獲得國家藥品監督管理局上市批准，在中國使用sac-TMT治療既往接受過至少2種系統治療（其中至少1種針對晚期或轉移性階段）的不可切除的局部晚期或轉移性三陰性乳腺癌成人患者。
• 公司已啟動一項針對sac-TMT單藥對比ICC（研究者選擇的化療）用於一線治療晚期三陰性乳腺癌的3期註冊性研究。

HR+/HER2-乳腺癌：

• 2026年2月，sac-TMT用於治療既往接受過內分泌治療且在晚期階段接受過至少一線化療方案的HR+/HER2-乳腺癌成人患者的新適應症上市申請已獲國家藥監局批准。
• 一項針對sac-TMT對比ICC用於治療既往接受過內分泌治療的HR+/HER2-乳腺癌患者的3期註冊性研究正在進行中。

EGFR突變非小細胞肺癌：

• 2025年3月，該公司從國家藥監局獲得sac-TMT在中國用於治療既往接受過EGFR-TKI治療和鉑類化療失敗的EGFR突變陽性非小細胞肺癌成人患者的上市批准。這是全球首個獲批用於肺癌治療的TROP2 ADC藥物。
• 2025年10月，該公司從國家藥監局獲得sac-TMT在中國用於治療既往接受過EGFR-TKI治療後疾病進展的EGFR突變陽性非小細胞肺癌成人患者的上市批准。這是全球首個相比含鉑雙藥化療顯示出總生存期獲益，且獲批用於僅接受TKI治療後疾病進展的晚期非小細胞肺癌（二線治療）的ADC藥物。
• 一項sac-TMT聯合奧希替尼一線治療EGFR突變非小細胞肺癌的3期註冊性研究，以及一項sac-TMT單藥或聯合奧希替尼作為EGFR突變非小細胞肺癌新輔助治療的2期研究正在進行中。

EGFR野生型非小細胞肺癌：

• 一項sac-TMT聯合KEYTRUDAR^[1]（帕博利珠單抗）對比帕博利珠單抗用於PD-L1陽性非小細胞肺癌一線治療的3期註冊性研究已達到其主要終點。這是首個在非小細胞肺癌一線治療中達到主要終點的ADC聯合免疫檢查點抑制劑的3期臨床試驗。
• 2026年1月，sac-TMT聯合帕博利珠單抗用於PD-L1陽性非小細胞肺癌一線治療獲國家藥監局突破性療法認定。
• 一項sac-TMT聯合帕博利珠單抗用於PD-L1陰性非小細胞肺癌一線治療的3期註冊性研究正在進行中。

其他適應症：公司正積極探索sac-TMT單藥及聯合其他療法在治療其他實體瘤（包括胃癌、食管癌、宮頸癌、卵巢癌、尿路上皮癌、去勢抵抗性前列腺癌、頭頸部鱗狀細胞癌、甲狀腺癌等）方面的潛力。

注射用博度曲妥珠單抗(HER2 ADC)（亦稱A166）（商品名：舒泰萊R）

• 2025年10月，注射用博度曲妥珠單抗獲國家藥監局批准上市，用於治療既往接受過至少一種抗HER2治療的HER2陽性乳腺癌成人患者。這是中國首個獲批用於二線及以上HER2陽性乳腺癌的國產HER2 ADC藥物。
• 一項針對注射用博度曲妥珠單抗治療既往接受過拓撲異構酶抑制劑ADC的HER2陽性乳腺癌的開放、多中心2期臨床研究正在進行中。

關鍵臨床數據亮相國際學術大會及頂級期刊

• sac-TMT用於治療二線EGFR突變非小細胞肺癌的3期研究結果入選2025年歐洲腫瘤內科學會大會(2025 ESMO Congress) LBA（最新突破性摘要），並在主席研討會環節以口頭報告形式呈現。與化療相比，sac-TMT在客觀緩解率、無進展生存期和總生存期方面均取得了具有統計學顯著性和臨床意義的改善。該研究結果同時在線發表於《新英格蘭醫學雜誌》(New England Journal of Medicine)及2026年首期期刊。
• sac-TMT用於治療三線EGFR突變非小細胞肺癌的研究結果在美國臨床腫瘤學會年會(ASCO Annual Meeting)上以口頭報告形式呈現，並發表於《英國醫學雜誌》(British Medical Journal)。該研究的最終總生存期分析結果將入選2026年歐洲肺癌大會(ELCC)LBA，並以迷你口頭報告形式呈現。
• sac-TMT用於治療二線及以上HR+/HER2-乳腺癌的3期研究結果入選2025年ESMO大會LBA，並以口頭報告形式呈現。
• 注射用博度曲妥珠單抗用於治療二線及以上HER2陽性乳腺癌的3期研究結果入選2025年ESMO大會LBA，並以口頭報告形式呈現。

在研ADC藥物持續釋放價值，創新研發管線階梯推進

2期臨床階段

SKB315 (CLDN18.2 ADC)：

• SKB315的1b期臨床試驗正在進行中，用於治療胃癌/胃食管結合部癌/胰腺導管腺癌等。
• SKB315治療包括胃癌/胃食管結合部癌在內的晚期實體瘤患者的1期研究結果於2025年10月在2025年ESMO大會上發布。

SKB410/MK-3120 (Nectin-4 ADC)：

• 合作夥伴默沙東(MSD)已啟動了4項SKB410/MK-3120靶向膀胱癌等晚期實體瘤的全球1/2期臨床試驗。

SKB571/MK-2750（新型雙抗ADC）：2期臨床試驗正在中國進行。

SKB518（潛在同類首創靶點新型ADC）：2期臨床試驗正在中國進行。

SKB500（新型ADC）：2期研究正在中國進行。

1期臨床階段

SKB107 (RDC) ^[2]：1期研究正在進行中。

SKB535/MK-6204（潛在同類首創靶點新型ADC）：SKB535的1期臨床試驗正在中國進行。

SKB445（潛在同類首創靶點新型ADC）：SKB445的1期臨床試驗正在中國進行。

SKB105/CR-003 (ITGB6 ADC)：2026年1月，該藥用於治療晚期實體瘤的新藥臨床試驗申請已獲國家藥監局藥品審評中心批准。一項1/2期試驗正在中國進行。

非ADC資產戰略佈局，聚焦聯合療法與適應症拓展

腫瘤領域候選藥物

• 塔戈利單抗注射液（PD-L1單抗，亦稱A167）（商品名：科泰萊R）：2025年1月，該公司獲得國家藥監局批准，將塔戈利單抗聯合順鉑和吉西他濱用於鼻咽癌一線治療。塔戈利單抗是全球首個獲批用於鼻咽癌一線治療的PD-L1單抗。
• 2025年5月，塔戈利單抗聯合順鉑和吉西他濱用於鼻咽癌一線治療的3期臨床研究結果在ASCO年會上公佈。

西妥昔單抗N01注射液（EGFR單抗，亦稱A140）（商品名：達泰萊R）：

• 2025年2月，該公司獲得國家藥監局批准，將西妥昔單抗N01注射液聯合FOLFOX或FOLFIRI方案用於RAS基因野生型轉移性結直腸癌的一線治療。

富馬酸侖博替尼膠囊（RET抑制劑，亦稱A400/EP0031）（商品名：寧泰萊R）^[3]：

• 用於一線及以上治療RET融合陽性非小細胞肺癌的新藥上市申請已獲國家藥監局藥品審評中心受理。
• 該公司還在中國開展針對RET陽性甲狀腺髓樣癌及實體瘤的1b/2期臨床研究。
• Ellipses Pharma正在中國以外的地區推進其2期臨床研究。
• 2025年5月，富馬酸侖博替尼膠囊治療晚期RET突變型甲狀腺髓樣癌的1期研究結果在ASCO年會上公佈。

SKB118/CR-001（PD-1/VEGF雙抗）：

• 2026年1月，Crescent Biopharma宣佈其用於治療晚期實體瘤的SKB118新藥臨床試驗申請已獲FDA批准，啟動全球ASCEND 1/2期臨床試驗，首例患者已於2026年2月給藥。
• 公司計劃於2026年上半年在中國啟動SKB118的1/2期臨床研究。

自身免疫性疾病領域候選藥物

SKB378/WIN378（TSLP單抗）：

• 2025年1月，SKB378用於治療慢性阻塞性肺病的新藥臨床試驗申請獲國家藥監局批准。
• 合作夥伴Windward Bio已啟動針對哮喘患者的2期POLARIS全球試驗。

SKB575（TSLP/未披露靶點雙抗）：2026年3月，SKB575用於治療特應性皮炎的新藥臨床試驗申請獲國家藥監局批准。

其他非腫瘤疾病領域候選藥物

SKB336（FXI/FXIa單抗）：公司已完成在中國開展的1期臨床試驗。

多款產品首次納入國家醫保目錄，市場覆蓋加速

2025年，公司創新成果商業化呈現爆發式增長。公司還提交了富馬酸侖博替尼膠囊的新藥上市申請，預計在2026年下半年或2027年上半年啟動商業化，具體取決於監管溝通和上市批准。截至目前，公司由五款產品組成的初期商業化產品組合已初具規模。

在國家創新政策支持下，該公司成功推動三款商業化產品佳泰萊R、科泰萊R及達泰萊R首次納入國家醫保藥品目錄，並於2026年1月1日正式生效，有望更快更好地惠及更多患者。

全球合作穩步推進，綜合實力獲權威認可

與默沙東合作：截至本公告日期，默沙東正在評估已啟動的17項sac-TMT作為單藥或與帕博利珠單抗或其他藥物聯合用藥，用於治療多種癌症（包括乳腺癌、肺癌、婦科腫瘤、消化道腫瘤及泌尿系統腫瘤）的3期全球臨床研究。除sac-TMT外，該公司亦與默沙東就部分ADC資產展開合作，持續探索有優勢的ADC管線組合。

與Ellipses Pharma合作：公司深化了與Ellipses Pharma在A400/EP0031上的合作，該藥已獲FDA批准進入2期臨床開發階段。截至2025年12月31日，已在美國、歐洲及阿聯酋為富馬酸侖博替尼膠囊設立了39個臨床研究中心。

與Windward Bio合作：2025年1月，該公司及和鉑醫藥與Windward Bio簽訂獨家許可協議，據此，該公司與和鉑醫藥授予Windward Bio在全球範圍內（不包括大中華區及部分東南亞和西亞國家）研究、開發、生產和商業化SKB378/WIN378的獨家許可。Windward Bio已啟動針對哮喘患者的2期POLARIS全球試驗。

與Crescent Biopharma合作：2025年12月，該公司與Crescent Biopharma就SKB105/CR-003及SKB118（一種PD1 x VEGF雙抗，亦稱CR-001）達成戰略合作。根據合作，該公司授予Crescent Biopharma在美國、歐洲及大中華區以外的所有其他市場研究、開發、生產和商業化SKB105/CR-003的獨家權利。作為回報，公司從Crescent Biopharma獲得在大中華區研究、開發、生產和商業化SKB118/CR-001的獨家權利。

2026年1月，Crescent Biopharma宣佈其用於治療晚期實體瘤的SKB118新藥臨床試驗申請已獲FDA批准，啟動全球ASCEND 1/2期臨床試驗，首例患者已於2026年2月給藥。

ESG能力持續提升，築牢可持續發展根基

該公司通過建立並不斷完善ESG治理結構，全面提升ESG績效能力，確保公司可持續發展。2025年5月，該公司榮獲Extel「最佳ESG」獎。2026年3月，公司在MSCI ESG評級評估中獲得「AA」評級。

展望

2026年，科倫博泰將繼續推動創新，強化運營能力，朝著世界一流生物製藥公司的目標穩步邁進。具體而言，公司將實施以下發展戰略：推進針對具有重大醫療需求適應症的差異化研發管線；創新和優化毒素-連接子策略及新型偶聯藥物設計與結構，同時拓展非腫瘤疾病領域的應用；增強端到端的藥物開發和商業化能力；拓展業務版圖及戰略合作夥伴關係，提升公司在海外市場的開發、註冊及商業化能力；優化運營體系，致力成為全球領先的生物製藥公司。

關於四川科倫博泰生物醫藥股份有限公司

四川科倫博泰生物醫藥股份有限公司（簡稱「科倫博泰」，股票代碼：6990.HK）是四川科倫藥業股份有限公司的子公司，專注於創新生物藥和小分子藥物的研發、生產、商業化及全球合作。公司致力於解決全球及中國未滿足的臨床需求，戰略佈局腫瘤、自身免疫性疾病及代謝性疾病等重大疾病領域，並致力於打造國際化的藥物研發及產業化平台，旨在成為全球創新藥物領域的領導者。目前，科倫博泰擁有30余個重點創新藥物項目，其中4個項目（覆蓋8個適應症）已獲批上市，1個項目處於新藥上市申請階段，10余個項目處於臨床試驗階段。該公司還成功建立了享譽國際的專有ADC及新型偶聯藥物平台OptiDC^TM，已有2個ADC項目（覆蓋5個適應症）獲批上市，多個ADC及新型偶聯藥物項目處於臨床或臨床前開發階段。

Sands Gallery as bridge bringing Macao artists onto international art stage
Contemporary artworks presented alongside century-old firecracker history 
Showcasing vibrant energy of Macao's art and cultural scene

MACAO, March 24, 2026 /PRNewswire/ -- Sands China celebrated the grand opening of its Sands Gallery booth Tuesday at Art Central, Hong Kong's premier international art event. The booth features artworks by three of Macao's forward-looking, promising young artists – Lei Ieng Wai, Leong Chi Mou, and Dor Lio Hak Man – alongside a historical collection from "A Century of Iec Long Firecracker Factory in Radiance – An Exhibition on the Resonant History and Aesthetic Memory of Macao Firecrackers" currently on view at Sands Gallery in Macao. Together, the booth offers a magnificent display of Macao's enduring artistic charm to visitors.

Sands China's participation in Art Central reaffirms the company's commitment to promoting the development of art and culture in Macao. Since the establishment of Sands Gallery as a permanent art space in 2022, the company has consistently leveraged the gallery as a bridge connecting Macao artists with the global art world. Its debut appearance at Art Central not only brings emerging Macao artists onto an international stage, but also reflects the growing recognition of Sands Gallery within the international art scene. The opening day welcomed nearly 100 distinguished guests from Hong Kong and Macao to mark a new milestone in the development of Macao's art scene.

Sands China is the first integrated tourism and leisure enterprise from Macao invited as an Associate Partner to join Art Central. In alignment with the Macao SAR government's policy of diversified development, Sands China has long supported the integration of culture and tourism. Through presenting Sands Gallery at Art Central, the company seeks to further strengthen the gallery's role as an international cultural portal for Macao – a portal that helps Macao artists expand onto global platforms, thereby elevating the international competitiveness of Macao's arts and cultural sector and its talent development, while constantly fostering the city's vibrant and diversified development.

The Sands Gallery booth will be open to the public March 25-29, presenting more than 40 artworks, including distinctive pieces from the three Macao artists. Their works and artistic visions demonstrate a high international standard, while reflecting deep connections to Macao's urban life and cultural identity. Lei draws on scientific theory as the foundation of aesthetics, transforming artificial spectra, proportional values, and geometric structures into repetitive, precise blocks of colour and surfaces of light that reflect the fluidity and changes of urban life. Leong interrogates shifting notions of value and cultural interfaces that shape identity, informed by his personal migration history. His works examine the tension and intricate relations between Macao culture and artistic essence. Lio blends Japanese manga and Western painting into his practice in a distinctive approach, creating imaginative narratives and artistic spaces that resonate with both ordinary and philosophical experiences.

Dr. Wilfred Wong, executive vice chairman of Sands China Ltd., said: "Since the establishment of Sands Gallery in 2022, Sands China has been committed to fostering cultural exchange between Macao and the world – by leveraging the gallery as a bridge that brings the world of international art into Macao, while carrying Macao's rich artistic vision to the world. After four years of dedicated efforts, we are honoured to be the first integrated tourism and leisure enterprise from Macao participating in Art Central as an Associate Partner. Today, we are delighted to introduce three exceptionally promising young artists from Macao — Lei Ieng Wai, Leong Chi Mou, and Dor Lio Hak Man — showcasing their creative flair to international audiences. Through the power of art, we hope to bring the world closer and deepen people's understanding of one another.

"Macao is a city shaped by over four centuries of cultural exchange between East and West. To reflect this heritage, we are also presenting elements of our special exhibition, 'A Century of Iec Long Firecracker Factory in Radiance,' currently on view at Sands Gallery in Macao, enabling global audiences to experience this shared memory of Macao's vibrant days. By participating in this year's Art Central, we aim for Macao to be a wider international cultural portal, highlighting the stories of Macao artists — and to leverage art as a bridge for global understanding, so we may flourish and grow together."

Lei said: "I would like to express my gratitude to Sands Gallery for supporting me on my artistic journey. From participating in the collateral exhibition for Art Macao at Sands Gallery a few years ago to being here at Art Central today, every step has held great significance for me. The three series on display took me 10 years to complete, and their rich content reflects my unwavering dedication to artistic practice and exploration. With the support of Sands Gallery, I believe that we can use Art Central as a platform to exchange ideas with artists from around the world while elevating my work to new heights."

Leong said: "It was an honour to participate in a collateral exhibition for Art Macao at Sands Gallery a few years ago. I am honoured to join hands with the gallery once again to bring my recognised works to Art Central. Our participation in this prestigious art event not only opens a window for the future development of Macao's art and cultural industry, but also allows the city's distinctive artistic and cultural heritage to shine on the global stage. With the support of Sands Gallery and the showcase of my multimedia works that blend Eastern and Western cultures, we can unleash more opportunities to establish a presence on the global art scene and allow Macao artists to be seen by wider audiences."

Lio said: "It is my first time participating in Art Central, and I am truly honoured to have been invited to an international platform outside Macao to showcase my works to global audiences and connect with artists from around the world. I am grateful to Sands Gallery for providing Macao artists with such a valuable opportunity to pave the way onto the global stage, showcasing the city's creative flair to the world. Through this exhibition, I hope my works can reach more people and bring them a sense of resonance and joy, while demonstrating the strength of Macao's art scene to the world."  

Showcasing the diverse cultural heritage of Macao through contemporary art and century-old industrial craftsmanship

The Sands Gallery booth is also being presented in conjunction with "A Century of Iec Long Firecracker Factory in Radiance – An Exhibition on the Resonant History and Aesthetic Memory of Macao Firecrackers," currently on view at Sands Gallery in Macao. Marking the centenary of the Iec Long Firecracker Factory, the booth is also presenting original Macao firecracker packaging labels. Through artistic expression spanning different eras, the exhibition showcases the enduring innovation and creative vitality of Macao's arts and cultural landscape.

In addition, Professor Ung Vai Meng, distinguished professor of the Faculty of Humanities and Arts at the Macau University of Science and Technology and curator of the Iec Long firecracker exhibition, will host a seminar at the Art Central Theatre March 29. Titled "Aesthetics in a Square-Inch: A Century of Visual Culture Change Through Macao's Firecracker Packaging," the seminar will delve into the development and aesthetic spirit of Macao's firecracker industry, bringing the cherished memories of its century-old industrial heritage to the global stage.

The booth's opening brought together nearly 100 distinguished guests, including Macao government officials and representatives from the fields of art and culture, tourism, academia, and media. Moreover, Sands China specially arranged tours guided by professionals from Art Central for the guests to visit both the Sands Gallery booth and other participating galleries. The initiative aims to encourage Macao's various sectors to broaden their international horizons by fostering deeper exchanges with global artists, galleries, and collectors, thereby enhancing their artistic perspectives.

Guests of honour at Tuesday's opening ceremony were: Stanley Mok, general manager of the Macau Government Tourism Office Representative Office in Hong Kong; Corey Andrew Barr, fair director of Art Central; Lok Hei, president of the Macau Artist Society; Professor Ung;
Macao artists Lei, Leong, and Lio; Dr. Wong; and Devonne Iao, senior vice president and chief marketing officer of resort marketing for Sands China Ltd.

For more information about the Sands Gallery booth, please visit https://en.sandsresortsmacao.com/sands-lifestyle/sands-art-gallery/art-central-202603.html.

For more information about Art Central and ticketing, please visit artcentralhongkong.com.

About Sands Gallery

As an art space located at The Grand Suites at Four Seasons Hotel Macao, Sands Gallery is dedicated to bringing diverse art exhibitions to the city, fostering the sustainable development of Macao's cultural and creative industries.

Since its establishment in 2022, the gallery has hosted 12 exhibitions of varied styles, introducing artworks of international and national calibre while also providing opportunities for local artists to showcase their works and connect with the global art stage.

Through continued endeavours in Macao's arts and cultural sector, Sands China has built the Gallery into a platform of artistic weight and cultural depth, injecting multicultural vitality into Macao, enriching the artistic experiences of residents and visitors, and enhancing public appreciation of art. At the same time, it fully supports the Macao SAR government's policy of promoting travel development, contributing to Macao's growth as "a base for exchange and cooperation where Chinese culture is the mainstream and diverse cultures coexist."

About Sands China Ltd.

Sands China Ltd. (Sands China or the Company) is incorporated in the Cayman Islands with limited liability and is listed on The Stock Exchange of Hong Kong Limited (HKEx: 1928). Sands China is the largest operator of integrated resorts in Macao. The Company's integrated resorts on the Cotai Strip comprise The Venetian^® Macao, The Plaza^® Macao, The Parisian^® Macao and The Londoner^® Macao. The Company also owns and operates Sands^® Macao on the Macao peninsula. The Company's portfolio features a diversified mix of leisure and business attractions and transportation operations, including large meeting and convention facilities; a wide range of restaurants; shopping malls; world-class entertainment at The Venetian Arena, The Londoner Arena, The Venetian Theatre, The Parisian Theatre, The Londoner Theatre and Sands Theatre; and a high-speed Cotai Water Jet ferry service between Hong Kong and Macao. The Company's Cotai Strip portfolio has the goal of contributing to Macao's transformation into a world centre of tourism and leisure. Sands China is a subsidiary of global resort developer Las Vegas Sands Corp. (NYSE: LVS).

For more information, please visit www.sandschina.com.

About Art Central

Art Central, a cornerstone event of Hong Kong Art Month, presents the next generation of talent from Asia's most forward-thinking galleries alongside celebrated artists from across the globe. Since its inaugural edition in 2015, Art Central has established itself as a leading platform for innovation in contemporary art, advancing the profiles of artists and galleries and reinforcing their presence within the international art landscape. Today, the Fair is recognised for the strength of its curatorial programming and as a vital meeting point for discovery and exchange among collectors and curators representing private, corporate, and institutional collections worldwide.

Media contacts:

Corporate Communications, Sands China Ltd.

Mabel Wu

Tel: +853 8118 2268

Email: [email protected]

Jesse Chiang

Tel: +853 8118 2054

Email: [email protected]

Artist Profiles

「金沙藝廊」構築國際藝壇橋樑   攜澳門藝術家立足世界舞台
當代新銳與炮竹百年歷史並置    綻放澳門文化藝術蔚然實力

澳門2026年3月24日 /美通社/ -- 金沙中國於香港年度國際藝術盛會「藝術中環」（Art Central）設立的「金沙藝廊」展區今天盛大揭幕，聚焦呈獻三位澳門具前瞻性、國際潛力的青年藝術家——李英維、梁子毛及廖克敏之精湛作品，同場呈現澳門「金沙藝廊」現正展出的《流光溢彩‧益隆百年》澳門炮竹時代記憶與美學特展之歷史珍品，蔚然展示澳門歷久彌新的藝術氣韻。是次參展秉持金沙中國推動澳門文藝發展的長遠願景，自2022年成立常設藝術空間「金沙藝廊」以來，持續為本澳藝術家構建連接國際藝壇的橋樑，今獲邀進駐藝術中環此國際盛事，既成功引領本澳新銳藝術家邁進國際舞台，亦彰顯各界對「金沙藝廊」的高度認可。開幕當天氣氛熱烈，吸引港澳近100名嘉賓雲集支持，共同見證澳門藝術發展的新里程碑。

此次參展標誌著金沙中國成為澳門首家以「聯合合作伙伴」身份獲邀參與藝術中環的綜合旅遊休閒企業。金沙中國一直全力配合澳門特別行政區政府的多元發展方針，積極推動文化旅遊的融合發展；是次以「金沙藝廊」亮相藝術中環，旨在進一步發揮其作為國際文化窗口的橋樑作用，為澳門藝術家搭建更廣闊的國際藝術展示平台，引薦他們走出國際，以此提升澳門文藝事業及人才發展的國際競爭力，持續激發澳門的多元璀璨活力。

「金沙藝廊」展區合共呈獻逾40件藝術作品，並於3月25日至29日開放予公眾參觀。當中推薦三位澳門藝術家的代表佳作；他們的作品與藝術視野均展現國際高水準，並以各自藝術意涵回應澳門城市及文化的深層連結。李英維以科學邏輯為美學基礎，將光譜、比例與幾何結構轉化為層層推演的色塊與光面，映照出城市生活的流動與變化；梁子毛以「價值」與「文化駁口」為靈感軸心，結合自身移居經驗，探討澳門文化與藝術本質之間的張力與相生關係；廖克敏則以揉合漫畫與西洋繪畫的獨特筆觸，展開富想像的日常敘事，在平凡與哲思之間鋪陳出共鳴的藝術空間。

金沙中國有限公司行政副主席王英偉博士表示：「金沙中國自2022年成立『金沙藝廊』以來，始終秉持推動澳門文化與世界交流互鑑的初心，將國際藝術視野引進澳門，同時把本澳深厚藝術養分輸向世界。經過四年努力，我們很榮幸成為首家以『聯合合作伙伴』身份進駐藝術中環的澳門綜合旅遊休閒企業。今日，我們隆重推薦三位極具潛力的澳門青年當代藝術家——李英維、梁子毛及廖克敏，向國際觀眾呈現他們的創作力量，旨在透過藝術共鳴，讓世界彼此理解。澳門擁有四百多年中西文化交融的歷史底蘊，同場亦帶來現正於澳門『金沙藝廊』展出《流光溢彩‧益隆百年》特展的美學元素，冀讓國際觀眾感受澳門這段人間煙火的共同記憶。透過參與今屆藝術中環，我們冀開啟更廣闊的國際文化交流窗口，說好澳門藝術家的故事，進一步以藝術讓國際彼此認識，共同振翅高飛。」

藝術家李英維表示：「感謝『金沙藝廊』一直陪伴並推動我的藝術成長旅程，從數年前參與的『藝文薈澳』平行展，到今天給予機會於Art Central亮相，每一步都深具意義。是次展出的三個系列作品橫跨十年製作，內容豐富，同時見證著我在藝術方面的持續實踐及探索。在『金沙藝廊』的帶領下，相信定能在Art Central與世界各地的藝術家實現藝術層面上的交流與互動，並為我的作品開拓更高的世界觀。」

藝術家梁子毛表示：「數年前有幸參與『金沙藝廊』展出的『藝文薈澳』平行展，如今能再度與藝廊合作及參與藝術中環此盛事，我深感榮幸，也很高興我的創作再獲認可。是次藝廊進駐藝術中環，不僅為澳門文藝界未來發展開啟了一道窗口，亦讓本澳獨特的文藝底蘊在國際舞台上綻放光彩。在藝廊的推動下，並藉由我匯聚中西方文化的跨媒介作品，是次參展將為我們開創更多跨進世界藝壇的可能性，讓澳門藝術家被看見。」

藝術家廖克敏表示：「今次是我首次參與藝術中環，能走出澳門到更廣闊國際平台，讓更多觀眾親身欣賞我的作品，也有機會認識世界各地的藝術家，令我非常興奮與榮幸。感謝『金沙藝廊』給予這難能可貴的機會，為我們一眾澳門藝術家搭建走向世界的橋樑，並展示澳門的創作力量。透過今次出展，期盼我的作品能觸達及觸動更多觀眾，以藝術帶給大家共鳴與快樂，更讓世界認識澳門藝壇的實力。」

當代力作 x 百年工業藝術   呈現澳門多元文化底蘊
展區亦與澳門「金沙藝廊」現正展出的《流光溢彩‧益隆百年》澳門炮竹時代記憶與美學特展聯動策展，藉澳門益隆炮竹廠創立百年此時代印記為契機，展出多件澳門炮竹包裝招紙原稿珍品，透過跨時代的藝術表達，展示澳門文化藝術持續迸發的創新創造力。

此外，金沙中國邀請特展策展人、澳門科技大學人文藝術學院特聘教授吳衛鳴先生，在3月29日於藝術中環劇場舉行專題講座《方寸美學：從澳門炮竹包裝解讀百年視覺文化變遷》，向與會觀眾解讀澳門炮竹業的發展與美學理念，讓國際更好感悟澳門這段具百年工業歷史、承載著人間煙火的美學回憶。

展區開幕當天，匯聚了來自澳門政府、文化藝術、旅遊、學術及媒體界等近百位嘉賓親臨見證。金沙中國特地安排多場專業導賞，並由藝術中環團隊親自帶領一眾來賓參觀「金沙藝廊」展區及其他參展畫廊。此舉旨在鼓勵澳門各界放眼國際，藉促進本澳各行業與全球藝術家、畫廊及收藏家的深入交流、繼而提升藝術視野及高度。

出席周二開幕儀式的嘉賓包括：澳門特別行政區政府旅遊局香港代表總經理莫兆光；藝術中環展會總監Corey Andrew Barr；澳門美術協會會長陸曦；澳門科技大學人文藝術學院特聘教授、《流光溢彩‧益隆百年》澳門炮竹時代記憶與美學特展策展人吳衛鳴教授；澳門參展藝術家李英維、梁子毛、廖克敏；金沙中國有限公司行政副主席王英偉博士、高級副總裁兼首席度假村營銷總裁尤穎。

如欲了解「金沙藝廊」展區的豐富內容，請瀏覽https://tc.sandsresortsmacao.com/sands-lifestyle/sands-art-gallery/art-central-202603.html。

有關Art Central的最新資訊及購買門票，請瀏覽https://artcentralhongkong.com/zh/。

關於「金沙藝廊」
「金沙藝廊」為金沙中國旗下座落於澳門四季名薈的常設藝術空間，致力為澳門帶來豐富多元的藝術展覽，推動本澳文化創意產業的持續發展。

自2022年成立以來，藝廊已舉辦十二場風格多元的展覽，既引進國際及國家級規格的藝術作品，亦為本澳藝術家提供展示機會，助力他們接軌國際藝術舞台。

金沙中國藉由在藝術文化範疇持續投放資源，打造藝廊成為兼具藝術份量與文化深度的平台，為本澳注入多元文化力量，進一步豐富澳門居民及旅客的藝術體驗，提升大眾的藝術鑑賞能力；同時，全面配合特區政府推動非博彩發展的施政方針，助力澳門建設以中華文化為主流、多元文化共存的文化交流基地。

關於金沙中國有限公司
金沙中國有限公司（香港聯交所：1928，「金沙中國」或「公司」）是一所於開曼群島註冊成立的有限公司及在香港聯合交易所有限公司上市的公司。金沙中國是澳門最大的綜合度假村經營商，於路氹金光大道上設有澳門威尼斯人^®、澳門百利宮、澳門巴黎人^®，以及澳門倫敦人^® 等物業項目，同時擁有及經營位於澳門半島的澳門金沙酒店。公司旗下的各綜合度假村集合多樣化的娛樂消閒、商務設施及客運業務，包括大型會議及展覽場地、各式餐廳食肆、購物中心、於威尼斯人綜藝館、倫敦人綜藝館、威尼斯人劇場、巴黎人劇場、倫敦人劇場及金沙劇場舉行的世界級娛樂表演，以及來往港澳的金光飛航高速渡輪服務。公司在路氹金光大道的各物業發展項目，堅定並持續地為建設澳門成為世界旅遊休閒中心貢獻力量。金沙中國是全球度假村發展商拉斯維加斯金沙集團股份有限公司（紐約證券交易所：LVS）的附屬公司。

如欲索取更多相關資訊，請瀏覽網頁https://hk.sandschina.com/index.html。

關於藝術中環展會 
Art Central（藝術中環展會）是香港藝術周的重點盛事，展示亞洲最具生命力畫廊及新銳藝術家的前衛創作，以及全球藝壇巨匠的傑出作品。自2015年成立以來，展會已成為當代藝術創新的重要平台，助力藝術家與畫廊提升業界影響力，鞏固其在國際舞台上的地位。如今，展會以高水準的策展規劃備受認可，是全球私人、商業、機構藏家與策展人的重要匯聚地，為藝術探索與交流搭建至關重要的橋樑。

傳媒查詢：
金沙中國有限公司 – 企業傳訊部
胡美寶
電話：+853 8118 2268
電郵：[email protected] 

鄭文軒
電話：+853 8118 2054
電郵：[email protected]

藝術家簡介

HONG KONG, March 24, 2026 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor" or the "Company"; Stock Code: 1833.HK) announced its annual results for the year ended December 31, 2025. In 2025, the Company recorded total revenue of RMB5.47 billion, up 13.7% year on year; profit attributable to owners of the parent of RMB379.5 million, up 366.1% year on year; and adjusted net profit of RMB414.0 million, up 161.3% year on year. Meanwhile, the Company's revenue mix continued to improve. Revenue from the commercial insurance enablement business (F-end) reached RMB3.3 billion, representing a year-on-year increase of 11.0%. The corporate health management business (B-end) delivered particularly strong growth, with revenue surging 40.6% year on year to RMB1.3 billion, accounting for 23.9% of total revenue, up 4.6 percentage points year on year.

As the core flagship of Ping An Group's health and senior care strategic business segment, the Company aims to build a managed care model with Chinese characteristics. It continued to upgrade its "online, in-hospital, in-home, and in-company" service network and empower full-scenario services through medical AI, providing users with one-stop medical, health, and senior care solutions that are worry-free, time-saving, and money-saving.

Core Businesses Unlock Profit Potential, Accelerating the Development of a China-style HMO Model

In the commercial insurance enablement business, Ping An Good Doctor provides Ping An Group's retail customers with online and offline, one-stop, 24/7, proactive medical, health, and senior care services, helping Ping An Group's integrated finance business enhance the differentiated competitiveness of its products, support customer acquisition and retention, and increase customer value. During the period, first-year premium per new policy of health care customers and home-based senior care customers increased by 1.5 times and 4.6 times, respectively.

Meanwhile, the Company continued to deepen innovation in the insurance + health care synergies, promoting the further integration of membership services and insurance products. For customers with protection products such as critical illness and medical insurance, the Company launched the "An You Hu"（安有護） and "An You Yi"（安有醫） health service plans. For customers with wealth-management insurance products, it established a multi-tiered membership system. For example, under the "Yu Xiang Guo Yi" program designed for high-value customers, the Company developed an integrated traditional Chinese and Western medicine co-management solution featuring one-on-one consultations with Traditional Chinese Medicine masters, personalized conditioning plans, and full-process management and proactive follow-ups by TCM family doctors.

For pension insurance customers, the Company continued to upgrade its home-based senior care service system, introducing three service programs covering health care management, home safety assistance and professional care for seniors. As of the end of the reporting period, more than 240,000 customers were entitled to home-based senior care services.

On the corporate health management side, leveraging differentiated strengths such as professional experience in corporate health management, a global medical service network, global emergency assistance, professional in-company services, 24/7 family doctor consultations, and convenient in-home services, the Company continued to expand its corporate customer base and provide one-stop health management solutions for corporates. To date, Ping An Good Doctor has served more than 6,700 paying corporate clients, up 83.1% from a year earlier. At the same time, this business generated gross merchandise volume (GMV) of approximately RMB3.63 billion in 2025, further unlocking its commercial potential. During the reporting period, the Company provided each enterprise with tailored solutions, including Workplace Clinics, in-company activities, and digital health dashboards. Employees have access to full-scenario services such as health checkups, chronic disease management, medical visit assistance, consultations with renowned doctors, and convenient medication purchase. Meanwhile, its QR code payment service, "Ping An Health Pay" has been rolled out to more than 77,000 pharmacies, improving convenience and saving time for employees.

Strengthening "online, in-hospital, in-home, and in-company" Service Capabilities to Build a Full-scenario Closed Loop Value Chain

In 2025, the Company continued to improve its "online, in-hospital, in-home, and in-company" service system, further expanding its service network and enhancing service quality.

Online services, the Company leveraged traffic from Ping An Group's health and senior care ecosystem and external corporate clients and has upgraded its multi-tiered family doctor service system to provide policyholders and corporate employees with full-cycle, proactive health management services, while offering differentiated solutions for customers with different health conditions. During the period, chronic disease management services were used 16.9 million times, with customer satisfaction reaching 99%.

In-hospital services, the Company further expanded its offline service network and built a team of approximately 50,000 in-house and contracted external doctors. It has signed up more than 3,500 expert doctors in total, including 10 academicians / TCM masters and over 800 hospital presidents, vice hospital presidents, department heads, and discipline leaders. The Company also partnered with more than 5,100 hospitals, over 240,000 pharmacies, and over 4,400 health checkup providers.

In-home services, the Company's home-based senior care services have expanded to 100 cities nationwide. During the period, the average monthly active rate of home-based senior care services reached 84%, while the response rate of "Smart Guard" alarms reached 100%.

In-company services, the Company continued to build multiple Workplace Clinics with services such as health monitoring, consultation and physiotherapy, and health education. Through remote screens for health services, the Company provides employees with a face-to-face consultation experience, and connects resources across the "online, in-hospital, in-home, and in-company" service network, effectively addressing pain points such as uneven access to medical resources across regions.

In addition, the Company continued to advance service standardization. In family doctor services, it supported the release of China's first group standard in online family doctor services, the Remote and Internet-Based Health Service Standards for Family Doctors. In home-based senior care, the Company has contributed to the development of six industry group standards, including the Service Management Standards for Home-based Rehabilitation and Nursing. Ping An's home-based senior care service was also among the first to receive the five-star rating for "home-based eldercare steward" services from the China Quality Certification Centre (CQC). In chronic disease management, the Company participated in the development of the national group standard for Specifications for the Construction of Weight Management Centers, supporting the standardized development of the weight management industry.

Leading AI Adoption in Healthcare to Boost Gross Profit and Improve Efficiency

With continued policy support in China for the development of "AI + Healthcare" applications, AI healthcare has entered a stage of scaled deployment. Backed by its deep technological expertise, Ping An Good Doctor continued to improve its AI capabilities, strengthen its "data + model + scenario" closed-loop capabilities, and expand AI deployment across various healthcare service scenarios, with the benefits of AI empowerment becoming increasingly evident.

The Company continued to deepen its presence in serious medical scenarios, building a differentiated model that combines AI with human doctors. During the reporting period, it further upgraded its large multi-modal model Ping An Medical Master®, as well as five vertical AI models for key medical scenarios. It also launched an AI medical product suite including key products such as Renowned Doctor Digital Avatar, AI Family Doctor, and AI Senior Care Concierge, with over 11,300 diseases precisely diagnosed and an accuracy rate of 95.1% in AI Doctor-aided diagnosis/treatment. It also introduced the multidisciplinary team ("MDT") platform for complex diseases, which has already been deployed in breast cancer and other disease areas. The accuracy of MDT treatment plans for complex diseases approached 90%, and the platform will be extended to more disease areas in the future.

During the reporting period, AI delivered notable empowerment in user reach, gross profit growth, and operating efficiency. Annual users of AI Doctor reached nearly 12 million, and the "AI + human doctor" model achieved 100% coverage among Ping An Group's retail customers; AI contributed approximately 4.5% of the Company's gross profit. Taking consultation services as an example, with AI's support, the cost per consultation in the fourth quarter of 2025 decreased by approximately 45% year on year, reflecting AI's role in improving efficiency and reducing service costs.

As public health awareness in China continues to rise and population aging accelerates, demand for high-quality medical resources is expected to keep growing, creating greater opportunities for the medical and health industry. Looking ahead, with continued support from various favorable policies, the Company will remain focused on providing inclusive, high-quality medical, health and senior care services that are worry-free, time-saving and money-saving, while delivering sustainable returns to shareholders.

About Ping An Healthcare And Technology Company Limited 

Incorporated in 2014, Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", 1833.HK) is a flagship of Ping An Group's health and senior care ecosystem. The Company was listed on the main board of HKEX on 4 May 2018.

The Company is dedicated to advancing Ping An Group's "integrated finance + health and senior care" strategy. Leveraging its extensive payer resources of health and senior care services, broad service provider network, comprehensive service standards, and robust ecosystems, the Company has evolved into a leading provider of health and senior care management services.

The Company remains steadfast in its mission to bridge professional communication between doctors and patients and to provide health improvements for all. Guided by the vision of "providing every enterprise with a healthy workplace, every family with a dedicated doctor, and every user with a healthy, long life," the Company will accelerate the development of a China-style HMO Model, providing users with a "worry-free, time saving, and money-saving" one-stop medical, health, and senior care solution.